FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?

European Journal of Nuclear Medicine

Volumn 25, Issue 11, 1998, Pages 1495-1501

  Vansteenkiste, Johan F ^a   Stroobants, Sigrid G ^a   Dupont, Patrick J ^a   De Leyn, Paul R ^a   De Wever, Walter F ^a   Verbeken, Eric K ^a   Nuyts, Johan L ^a   Maes, Frederik P ^a   Bogaert, Jan G ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Emission computed tomography; Fusion images; Mediastinal staging; N2 disease; Non small cell lung carcinoma; X ray computed tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ANATOMY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DOUBLE-BLIND METHOD; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MEDIASTINAL NEOPLASMS; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031740895     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050327     Document Type: Article

References (30)

1. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-323.
2. Webb WR, Gatsouris S, Zerhouni HA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiology Diagnostic Oncology Group. Radiology 1991; 178:705-713.
3. Dillemans B, Deneffe G, Verschakelen J, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg 1994; 8:37-42.
4. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60: 2682-2689.
5. 3H-2-deoxyglucose retention in murine tumor models. Nucl Med Biol 1996; 23:553-541.
6. Wahl R, Hutchins G, Bushsboaum D, Liebert M, Grossman H, Fisher S. F-18 fluoro deoxyglucose uptake into human tumor xenografts. Cancer 1991; 67:1544-1550.
7. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI. Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377.
8. Chin R, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995; 152:2090-2096.
9. Patz EF, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995; 108:1617-1621.
10. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153: 417-421.
11. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996; 23:741-747.
12. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
13. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111:642-648.
14. 18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994; 58:698-703.
15. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1581.
16. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Chest 1997; 112:1480-1486.
17. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16:2142-2149.
18. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Surg 1978; 76:832-837.
19. Goldstraw P, Rocmans P, Ball D, et al. Pretreatment minimal staging for non-small cell lung cancer: an updated consensus report. Lung Cancer 1994; 11 Suppl 3:1-4.
20. Shepp LA, Vardi Y. Maximum likelihood reconstruction for emission tomography. IEEE Trans Med Imag 1982; 1:113-122.
21. Maes F, Collignon A, Vandermeulen D, Marchai G, Suetens P. Multi-modality image registration by maximization of mutual information. IEEE Trans Med Imag 1997; 16:186-197.
22. Goldstraw P, Mannam G, Kaplan D, Michael P. Surgical management of non-small cell lung cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 1994; 107:19-28.
23. Pearson F, DeLarue N, Ilves R, Todd T, Cooper J. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83:1-11.
24. Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. The Leuven Lung Cancer Group. Ann Thorac Surg 1997; 63:1441-1450.
25. Klastersky J, Burkes R, Choi NC, et al. Induction therapy for NSCLC: a consensus report. Lung Cancer 1991; 7:15-17.
26. Martini N, Flehinger B. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67:1037-1049.
27. Goldstraw P. The practice of cardiothoracic surgeons in the perioperative staging of non-small cell lung cancer. Thorax 1992; 47:1-3.
28. Kumar P, Herndon J, Langer M, et al. Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2). Cancer 1996; 77:2393-2399.
29. Vansteenkiste J, De Leyn P, Deneffe G, et al. Present status of induction treatment for N2 non-small cell lung cancer: a review. Eur J Cardiothorac Surg 1998; 13:1-12.
30. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996; 9:410-414.